Skip to content

NIH BRAIN Invasive Neural Recording R61 Eligibility

Updated 5 official sources

Quick Answer: NIH BRAIN invasive neural recording R61 eligibility is strongest when a team has access to human invasive recording or stimulation opportunities and can use that access for 5 exploratory goals: feasibility, planning, neuroethical practice, data standards, and a future research-project path.

Full answer and how we checked it

According to Simpler.Grants.gov, RFA-DC-27-004 lists $6,000,000 in program funding, 5 expected awards, and a $700,000 award maximum.

This guide is for human neuroscience teams that don't know whether their project is exploratory BRAIN research, device translation, or a clinical-trial route.

Who this is for: Neuroscience investigators, neurosurgery collaborators, epilepsy-monitoring teams, neuroethics partners, and sponsored-research offices deciding whether a human invasive recording project belongs in this BRAIN R61 rather than an R01, R21, device route, or clinical-trial NOFO.

Data note: This guide uses the NIH BRAIN invasive neural recording R61 opportunity (opens in a new tab), the RFA-DC-27-004 full announcement (opens in a new tab), NIH BRAIN Initiative (opens in a new tab) context, the live BRAIN R61 program page, and NIH RePORTER records for the prior notice, checked on October 12, 2026.

In this guide

Quick Facts

Agency
HHS
Deadline
Feb 11, 2027
Status
Open

Assistance Listing 93.242: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.242, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
1,874
Avg Award (whole listing)
$2,471,098
Median Award (whole listing)
$1,407,686
Total Funding (FY2024, whole listing)
$1.8B
YoY Funding Trend
-1.1%

Data last verified: May 18, 2026

This BRAIN R61 is not a broad neuroscience grant. According to Simpler.Grants.gov (opens in a new tab), RFA-DC-27-004 seeks exploratory projects using invasive neural recording and stimulation technologies in the human brain. The key phrase is "exploratory research and planning." The award is meant to set up feasibility and a later research-project path, not to run a treatment trial.

Use this guide with the live BRAIN R61 program page, then compare it with NIH grants complete guide, NIH R01, R21, R03, and K awards, how grant reviewers score applications, what is a NOFO, and how to write a federal grant proposal. BRAIN concepts tend to get weaker when teams overclaim clinical impact and underwrite the fundamental neuroscience logic. This R61 needs the opposite posture.

What official NIH pages don't tell you is whether rare invasive access is enough to justify this route. Grantsights analysis of the full announcement compares the R61 opportunity, BRAIN program intent, clinical-trial limits, award maximum, access evidence, and later-grant path. That comparison changes the next action: apply when human invasive access creates a fundamental neuroscience question, skip when the project is mainly treatment testing, device translation, or noninvasive data collection.

For example, a team with epilepsy-monitoring access, a signed neurosurgery partner, and a neuroethics workflow could be strong even before R01-scale data exists. The NOFO itself says preliminary data on feasibility aren't required. A team with only a theory and hoped-for future patient access should not use the R61 to fill that gap. The better route may be R21, R01, NextTech, SBIR/STTR, or a clinical-trial path.

NIH BRAIN R61 Eligibility: 5 Fit Tests

5 fit tests should be passed before writing. According to Grants.gov, via the Simpler.Grants.gov listing (opens in a new tab), many applicant organization types are eligible, including higher education, nonprofits, for-profits, governments, tribes, and school districts. According to NIH, in the full announcement (opens in a new tab), non-U.S. entities and non-U.S. components of U.S. organizations are not eligible, but foreign components are allowed. The same notice says NIH will no longer issue awards that involve foreign subawards or subcontracts, so plan any international collaboration with that limit in mind.

Fit testStrong BRAIN R61 signalRed flag
Human invasive accessTeam has realistic access to recording or stimulation data from invasive proceduresAccess is speculative
Neuroscience questionProject asks a fundamental human brain questionProject mainly treats disease
Exploratory scopeAims establish feasibility and plan a later grantAims look like a full R01 in disguise
Standards and ethicsData sharing, practice standards, and neuroethics are built inThese are postponed
Team shapeNeuroscience, clinical, quantitative, and ethics skills are all presentOne discipline carries the whole plan

The common mistake is using the clinical setting as the whole argument. Access to implanted electrodes or surgical recordings is rare, but access alone is not enough. Reviewers need to see a question about human brain function that could not be answered as well with noninvasive methods or standard clinical data.

Funding, Timing, and Award Math: $6M, 5 Awards, $700K Maximum

$6,000,000 in program funding and 5 expected awards make the opportunity meaningful but selective. According to the RFA-DC-27-004 full announcement (opens in a new tab), NIH intends to commit about $6M in total costs to fund about 5 awards per receipt date. The posted date was May 4, 2026, the first due date was June 9, 2026 (now passed), and the second and final due date is February 11, 2027, at 5:00 PM local time, with the NOFO expiring February 12, 2027. The listing also says cost sharing is not required and the instrument type is a grant.

The $700,000 figure needs a careful read. The notice says budgets may not exceed $700,000 in direct costs in any single year, with consortium facilities and administrative costs excluded from that cap, and the maximum project period is 3 years. So it's a yearly direct-cost ceiling, not a lifetime total.

FactSource-backed read
Opportunity numberRFA-DC-27-004
Posted dateMay 4, 2026
Due datesJune 9, 2026 (passed); February 11, 2027
Review and council for the February roundJuly 2027 review, October 2027 council, December 2027 earliest start
Budget cap$700,000 direct costs per year
Project periodUp to 3 years
Program fundingAbout $6,000,000 total costs per receipt date
Expected awardsAbout 5 per receipt date
Award maximum$700,000

The NOFO lists 10 assistance listings, from 93.173 (NIDCD) to 93.853 (NINDS), because 10 BRAIN Initiative institutes and centers take part. That breadth doesn't make the award bigger: the R61 is still a limited exploratory route. Don't write it as if it were a full R01.

What Funded BRAIN R61 Projects Look Like

4 R61 projects were funded under RFA-DC-24-001, the notice this one reissues, according to an NIH RePORTER (opens in a new tab) API pull Grantsights ran on October 12, 2026. Every one is a basic human-cognition question built on intracranial recording, not a treatment study.

ProjectOrganizationTopicFY2025 total award
R61DC021924University of Colorado DenverNeocortical microarchitecture of executive function with large-scale intracranial recording$881,048
R61DC021925University of ChicagoCausal mapping of episodic memory iEEG networks with multi-method stimulation$787,743
R61DC022830NYU School of MedicineHuman hippocampal oscillations during visuomotor exploration$1,049,678
R61DC022835Cedars-Sinai Medical CenterNeuronal mechanisms of learning and using abstract representations$1,099,402

Grantsights checked the full announcement against those RePORTER records. For example, NYU received $1,049,678 in FY2025 for its hippocampal oscillation project, and $955,384 in FY2026. Grantsights analysis of those records shows the pattern: academic medical centers with active epilepsy-surgery programs, aims about memory, executive function, or learning, and total yearly awards between about $681,000 (Chicago, FY2026) and $1.1 million (Cedars-Sinai, FY2025) once indirect costs are added. If your topic is a disease mechanism or a stimulation therapy, notice that the related BRAIN awards treating depression, tremor, and Parkinson's disease came through a different notice (RFA-NS-21-024, a UH3 route), not this R61.

How Reviewers Score This R61

3 scored factors drive the overall impact score, and the notice adds questions specific to this program under each one. Under Importance of the Research, reviewers ask whether the project takes full advantage of direct brain access during surgery and how it lays the groundwork for a later research project grant. Under Rigor and Feasibility, they ask why the work must be done in humans rather than animals, how the implanted device or the patient's own condition could confound results, and whether the neuroethics plan holds up. Under Expertise and Resources, they look for a team that mixes clinicians, scientists, device engineers, computational scientists, regulatory experts, and ethics specialists.

Two attachments are easy to miss, and both can stop review. A 1-page team management plan that lays out the team structure and sets up a Scientific Steering Group is required, and the notice says applications without it won't be reviewed. The human subjects section must cover consent for participants who get no direct benefit, risk beyond standard clinical care, device maintenance and removal, and a long-term plan for patients after the study; applications that skip neuroethics will be withdrawn as incomplete. Funded teams also join an NIH-coordinated consortium working group on shared standards and data, so budget for that time.

BRAIN R61 vs R01, R21, Device, and Clinical-Trial Routes

5 adjacent routes can look similar. The route choice depends on whether the project is exploratory human neuroscience, device translation, clinical treatment, or a mature mechanistic study.

RouteBetter first read when...Why it may beat BRAIN R61
BRAIN R61Human invasive access enables exploratory neuroscienceProgram intent matches the rare data opportunity
Parent R01Preliminary data and aims are already matureFull research-project scale may fit better
R21The concept is exploratory but not invasive-human specificSimpler scope may be enough
NextTech R18Device readiness is the bottleneckTranslation, not neuroscience planning, is central
Clinical-trial NOFOIntervention testing is the projectThis R61 is clinical trial not allowed

For broader NIH mechanism choice, use NIH R01, R21, R03, and K awards. If the project is a device-readiness bridge, use the NIH NextTech R18 guide. If it is ordinary exploratory research without invasive human access, the NIH parent R21 (clinical trial not allowed) guide or the NIH grants complete guide may point to a cleaner route. Teams whose human work is mainly about building new recording sensors should compare the BRAIN next-generation sensor U01 guide.

What NIH Doesn't Tell You

4 gaps matter. NIH tells you the scientific scope and eligibility rules. It does not tell you whether your team has enough trust, access, and coordination discipline to run this work well.

First, NIH doesn't pre-score the access plan. Human neuroscience proposals can have good science but a fragile source of recordings. If the team cannot show realistic patient flow, surgeon commitment, data capture, and consent workflows, the application can look risky.

Second, NIH doesn't decide whether the question is fundamental enough. A treatment endpoint can appear in the background, but the core should be human brain function, dynamics, sensation, perception, memory, behavior, or related mechanisms.

Third, NIH doesn't write the neuroethics plan. For invasive work, reviewers expect more than a compliance paragraph. They need to see participant burden, incidental findings, data stewardship, communication, and how clinical care stays separate from research goals.

Fourth, NIH doesn't force you to pick a later path. The R61 should make a later project possible. If the application cannot say what a successful next grant would be, the planning logic is weak.

5 Real-World BRAIN R61 Scenarios

5 scenarios show the route decision. A hospital with an epilepsy monitoring unit, a computational neuroscience team, and a neuroethics partner may have a serious R61 case if the project uses rare invasive recordings to answer a fundamental brain question. A neurology group using routine clinical recordings only to predict treatment response may need a different route.

ScenarioBetter routeReason
Rare invasive recordings answer a human neuroscience questionBRAIN R61Fits the exploratory human access purpose
Mature mechanistic project with strong dataR01R61 may be too small
Noninvasive EEG or imaging onlyR21 or R01Invasive-access focus is missing
Device optimization for human readinessNextTech R18Device translation is the center
Patient intervention trialClinical-trial routeThis R61 does not allow clinical trials

An investigator studying memory encoding with recordings collected during clinically indicated surgery, with a clear plan for data standards and a later R01, is the kind of project that deserves a close read. A startup building an implant should look at NextTech or the NIH SBIR/STTR guide first, because the device path may matter more than the R61's exploratory planning frame.

7 Draft Checks to Run First

7 checks can prevent a weak BRAIN R61 application. The best drafts make access, ethics, and the future research path concrete, starting with specific aims that read as exploratory rather than R01-sized.

  1. The invasive human recording or stimulation source is specific.
  2. The neuroscience question is not just a clinical endpoint.
  3. The exploratory aims fit the $700,000 yearly direct-cost cap and the 3-year maximum.
  4. The consent and neuroethics plan is active.
  5. Data standards and sharing are addressed.
  6. The team includes clinical, quantitative, and neuroscience leadership.
  7. The later grant path is named.

According to Grants.gov, via Simpler.Grants.gov (opens in a new tab), this opportunity has $6,000,000 in program funding, 5 expected awards, and a $700,000 award maximum, and February 11, 2027 is the last due date. None of those numbers matter until the team can give one honest answer: is this project truly built around invasive human neuroscience access?

Grantsights Trust Check: Apply or Skip This Path

February 11, 2027 is the only due date left before the NOFO expires on February 12, 2027, so the apply-or-skip call has to happen early enough to line up surgical partners, IRB review, and the team management plan. Use the table below as the last screen before your team commits writing time.

Decision pointApply ifSkip or pause if
Human accessA neurosurgery or epilepsy-monitoring partner has signed on and patient flow is documentedAccess depends on a partner you haven't confirmed
Scientific questionThe aims ask how the human brain works, not whether a treatment helpsThe core outcome is safety, efficacy, or device improvement, which the NOFO lists as not responsive
Required attachmentsThe 1-page team management plan and the neuroethics and long-term patient care plans can be drafted nowEither plan would be written in the final week
Budget and periodThe work fits $700,000 in direct costs per year over 3 years or lessThe plan only works at R01 scale
Next stepA later research project grant is named in the planNo follow-on path is clear yet

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 1,874 Assistance Listing records | Avg: $2.5M

REAL DATA
1

The Johns Hopkins University

MD

$270.0M
2

Rutgers, the State University

NJ

$179.7M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

Who is the NIH BRAIN invasive neural recording R61 for?

It is for teams using invasive neural recording or stimulation opportunities in humans to answer fundamental neuroscience questions through exploratory research and planning.

How much funding is listed for the BRAIN R61?

Simpler.Grants.gov lists $6,000,000 in program funding, 5 expected awards, and a $700,000 award maximum for RFA-DC-27-004. The NOFO says NIH plans about $6M in total costs for about 5 awards per receipt date, and the $700,000 is a direct-cost cap per year.

When does the BRAIN R61 close?

The NOFO lists two due dates: June 9, 2026, which has passed, and February 11, 2027, the last one before the NOFO expires on February 12, 2027.

Are foreign organizations eligible?

No. The listing says non-U.S. entities and non-U.S. components of U.S. organizations are not eligible, but foreign components are allowed.

Who should skip this BRAIN R61?

Skip it if the project is a treatment trial, a noninvasive-only study, or a routine clinical data collection effort without a fundamental human neuroscience question.

Last updated October 12, 2026. Corrected October 12, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.